Repression of E-cadherin by the polycomb group protein EZH2 in cancer
about
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancerFunctional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expressionAn integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progressionA transcriptional repressor co-regulatory network governing androgen response in prostate cancersH3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependencyCovalent histone modifications--miswritten, misinterpreted and mis-erased in human cancersPharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancerEZH2 methyltransferase and H3K27 methylation in breast cancerHDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesPost-translational modification-regulated leukocyte adhesion and migrationTargeting EZH2 in cancerEmerging Transcriptional Mechanisms in the Regulation of Epithelial to Mesenchymal Transition and Cellular Plasticity in the KidneyPolycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic ImplicationsEpithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistanceLong non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasisPancreatic Cancer, A Mis-interpreter of the Epigenetic LanguageEpithelial-mesenchymal transition and cancer stemness: the Twist1-Bmi1 connectionThe role of EZH2 in tumour progressionSorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cellsEpithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.Gene profiling suggests a common evolution of bladder cancer subtypesDietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells.Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells.Epigenetic regulation of epithelial-mesenchymal transitionThe Effect of Sodium Valproate on the Glioblastoma U87 Cell Line Tumor Development on the Chicken Embryo Chorioallantoic Membrane and on EZH2 and p53 Expression.Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer.Long noncoding RNA-EBIC promotes tumor cell invasion by binding to EZH2 and repressing E-cadherin in cervical cancerFunctional and therapeutic significance of EZH2 in urological cancersDeletion analysis of BMI1 oncoprotein identifies its negative regulatory domainRearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaRegulation and Role of EZH2 in CancerInterrogating genomic and epigenomic data to understand prostate cancerMolecular genetics of prostate cancer: new prospects for old challengesFunction of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score.The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.miRNA control of tumor cell invasion and metastasis.Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancerMicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell linesVEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy
P2860
Q21091136-502934A6-739A-4D7E-BF65-300DA899677AQ21198854-1026F040-63B8-44FF-8164-F20D9B1A15F3Q24313269-20AF4358-427D-49BD-9050-B1A9BF9F0817Q24317244-E9AFC650-E79A-4203-8B07-E085537EBDFCQ24322697-8D25CF98-9FD8-4714-A7F2-9222F1CE978DQ24605342-4182118D-CC26-4C58-9847-054033926B9FQ24632276-E7CBDB17-9CFE-435A-97D3-23869480BD82Q24633788-C56A2A85-59BF-4396-B2E4-64AF89FB6A48Q26739120-80067DDE-3DBF-472A-B430-B651FF900877Q26753208-0F04292F-E20F-4D3E-948D-C38BBE5A14C4Q26769027-E5F16024-0B7B-4477-BA39-4A20E8B8FBF5Q26771698-EF2D2CF1-2E15-400C-AC9D-74E2A6E76EB5Q26801380-7D11BD6A-6BB4-49C4-AD32-72C6CA0CC847Q26824386-675A50E1-2241-4605-8F6B-DDA65086431BQ28066271-61D2C4E7-47AE-4378-AF4E-864D739688ABQ28079735-ACF55504-BBA5-4765-9982-E30886479693Q28248085-4BA94605-0BAA-4C80-961F-A28A10B1B969Q28255886-AF6505DA-3ADC-4F6D-9D2D-19DF55D18022Q28533484-D5144229-9554-4B85-9EC4-8F7D457E8BE1Q33351622-F98839C5-4288-4191-960A-BA2D3436CA8BQ33514281-8FDBDD7F-431F-45F3-8BA8-2587B694BCBBQ33589389-B12E111D-349F-4E1B-A3A0-3E220BF07337Q33705232-2FD8E604-52CB-47B5-972D-B9FAB285CC8FQ33756164-6E04A8B9-EA79-40AD-B1AB-39FEC9E09173Q33764436-9CB4DC31-E6DF-4290-9A79-0B9AAB9EF540Q33794860-CC91604D-70CA-44B3-BB06-0B6530A76620Q33829653-54B48D7F-5FEB-44E9-908D-191B09909F6AQ33875021-D739DDA5-A7BE-4385-930F-C9D8BC0A361CQ33914244-04D6A2CA-1995-44A4-9B07-03ECDB5EAAC6Q33975692-1F8BE0E5-C432-438A-B6EF-8A969254220DQ33992803-0C2DAC63-DF60-416E-91C4-0E43C1AD5706Q34043370-541D1548-0679-496E-A878-CC974807066EQ34125866-93D4EDB7-ED43-4857-8AEF-506EEB86AA0AQ34127462-A2C97390-E2DA-407D-A213-BA9B72162262Q34130249-75B70A62-C948-458F-923E-AB75014960BAQ34137728-862CD8CC-9FB9-4B0C-9096-2590AAEA9EF3Q34179359-9C0FFA1E-0154-4371-B0FD-655A2B70226BQ34197861-2832F01B-BA12-49B9-A4C7-63A5338879E8Q34201826-C4400D8A-0149-4731-B7F2-529C65B6172AQ34310069-8838D348-980E-4679-887B-AB671C473D47
P2860
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
@en
Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
@nl
type
label
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
@en
Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
@nl
prefLabel
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
@en
Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
@nl
P2093
P2860
P356
P1433
P1476
Repression of E-cadherin by the polycomb group protein EZH2 in cancer
@en
P2093
A M Chinnaiyan
S A Tomlins
S M Dhanasekaran
P2860
P2888
P304
P356
10.1038/ONC.2008.333
P407
P577
2008-09-22T00:00:00Z
P5875
P6179
1046327348